Browse the evidence

Continuous positive airway pressure (CPAP) is the best treatment option for obstructive sleep apnea (OSA).

Practitioners should prioritize CPAP as the primary treatment for patients diagnosed with OSA.

Telemedicine may improve compliance with CPAP treatment for obstructive sleep apnea.

Incorporating telemedicine strategies may help practitioners improve patient adherence to CPAP therapy.

Twenty percent (n = 24) of the five-year completers achieved remission from type 2 diabetes.

Practitioners can consider very low carbohydrate diets as a viable option for achieving diabetes remission.

The Diet Satisfaction Score consists of 10 items measuring one dimension with a Cronbach's alpha of 0.85.

Clinicians can use the Diet Satisfaction Score to assess diet satisfaction reliably.

Test-retest reliability of the Diet Satisfaction Score was good with an intraclass correlation coefficient of 0.64.

The Diet Satisfaction Score can be reliably used over time in clinical settings.

Each 1-point increase in Diet Satisfaction Score was associated with longer diet duration by 1.7 weeks.

Higher diet satisfaction may lead to longer adherence to dietary changes.

34.9% of coronary heart disease (CHD) patients were obese at hospitalization.

Practitioners should be aware that a significant proportion of CHD patients are obese.

19.5% of obese patients lost ≥5% of weight by the time of the study visit.

Weight loss interventions may be effective for a minority of obese CHD patients.

Tirzepatide is an efficacious and safe agent for the treatment of Type 2 Diabetes Mellitus (T2DM).

Practitioners can consider tirzepatide as a treatment option for managing T2DM.

Tirzepatide treatment resulted in a significant decrease of bodyweight compared with the vehicle treatment.

Tirzepatide may be effective for weight management in obese populations.

Tirzepatide treatment significantly decreased serum glucose levels after fasting and improved glucose tolerance compared with semaglutide treatment.

Tirzepatide may offer better glycemic control than semaglutide in obese individuals.

The relative effectiveness of intensive lifestyle intervention (ILI) on cardiovascular disease (CVD) incidence is inversely related to baseline frailty index (FI) in a graded fashion.

Practitioners should consider the frailty status of patients when recommending lifestyle interventions for CVD risk reduction.

Individuals in the first tertile of frailty index experienced a relative benefit from ILI with a hazard ratio of 0.73.

Less frail individuals may benefit more from intensive lifestyle interventions for CVD risk reduction.

Both FAST and SLOW repetition tempos produced similar increases in muscle thickness at the proximal portion of the quadriceps.

Practitioners can use either tempo for muscle thickness gains in trained individuals.

Menstrual frequency increased in all groups from baseline to 12 months.

This suggests that while HIT did not specifically improve menstrual frequency, overall menstrual frequency improved over time.

More participants became pregnant in the low-volume HIT (LV-HIT) group compared to the control group.

This indicates that low-volume HIT may have a positive effect on fertility in women with PCOS.

There is no single mode of physical activity that is superior for weight loss or prevention of weight gain.

Advise clients that various forms of physical activity can be effective for weight management, and they should choose what they enjoy.

T2DM control was satisfactory after LSG at mid- and long-term follow-up.

Laparoscopic sleeve gastrectomy is effective for long-term diabetes management in obese patients.

All exercise bouts increased mRNA expression of MYOD1 and MYF6 over time.

Engaging in exercise can enhance the expression of key myogenic factors involved in muscle growth.

Factors linked to greater weight loss on liraglutide include being female, not having diabetes, having relatively high baseline weight, and losing at least 4% of initial weight after 16 weeks of treatment.

Healthcare providers should consider these factors when predicting weight loss outcomes for patients on liraglutide.

Baseline body mass index, race, and age seem less relevant for predicting weight-loss response to liraglutide.

Providers may deprioritize these factors when assessing weight loss potential with liraglutide.

Preoperative semaglutide use in patients with type II diabetes mellitus undergoing arthroscopic rotator cuff repair was associated with a lower incidence of any adverse events (11.0% vs 27.4%), severe adverse events (3.5% vs 10.5%), and minor adverse events (8.5% vs 22.0%) within 90 days post-surgery.

Practitioners may consider semaglutide as a beneficial preoperative intervention to reduce postoperative complications in diabetic patients.

Patients not using semaglutide had a greater odds ratio of experiencing any adverse events (3.65) and severe adverse events (3.62) compared to those using semaglutide.

Highlighting the importance of semaglutide in reducing the risk of complications may guide preoperative decisions.

Patients not using semaglutide had a higher 2-year rotator cuff retear rate (18.3% vs 12.5%) compared to those using semaglutide.

This finding suggests that semaglutide may improve long-term surgical outcomes in diabetic patients.